Fig. 1: CarboCell allows for flexible administration and provides sustained intratumoral release of drug combinations with high tumor retention and minimal systemic spillover. | Nature Communications

Fig. 1: CarboCell allows for flexible administration and provides sustained intratumoral release of drug combinations with high tumor retention and minimal systemic spillover.

From: An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses

Fig. 1

a CarboCell is compatible with clinical injection technologies, including image-guided endoscopy, enabling treatment of most lesions (left). Upon contact with tissue or water it self-assembles into a depot (right). b The main constituents of CarboCell are the esterified carbohydrate sucrose octabenzoate (SuBen), the triglyceride glycerol trioctanoate (GTO), the TLR7/8a Resiquimod (R848) and the TGFβi RepSox. c R848 and RepSox release profiles from two CarboCell compositions (CC and CC-ER, Supplementary Table 1) were evaluated by s.c. injection of 50 μL CarboCell in mice [n = 3 per time point] and is presented as percent cumulative release of the total amount injected. Drug retention was quantified by HPLC of excised CarboCell. d Blood concentration [n = 4 per time point] and (e) intratumoral activity of R848 administered intratumorally (i.t.), intravenously (i.v.), or intratumorally via CarboCell (CarboCell TLR) was determined by liquid scintillation counting (LSC) using 3H-R848 [n = 4 per time point]. 3H-R848 was formulated in PBS or CarboCell (CC-4 (Supplementary Table 1)). The results are presented as mean ± SEM. Source data are provided as a Source Data file. Illustration created with BioRender.com, released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license.

Back to article page